Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501189 | 0.73 | MAPT (0.43) | PIM1CYP19A1 | |
| SCHEMBL1378443 | 0.73 | MTNR1A (0.47) | CYP19A1 | |
| SCHEMBL4506993 | 0.72 | MTNR1A (0.55) | MDM2CYP19A1 | |
| SCHEMBL1379412 | 0.71 | MTNR1A (0.59) | CYP19A1 | |
| SCHEMBL1376806 | 0.67 | MTNR1A (0.47) | — | |
| SCHEMBL4507171 | 0.66 | MDM2 (0.34) | MDM2 | |
| SCHEMBL4485409 | 0.62 | MTNR1A (0.49) | — | |
| SCHEMBL4493012 | 0.60 | KIF11 (0.34) | CYP19A1 | |
| SCHEMBL7674106 | 0.59 | CYP19A1 (0.48) | CYP19A1 | |
| SCHEMBL3676809 | 0.55 | KDM4E (0.55) | PIM1CLK4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | PIM1 2057/4885CLK4 3881/4885MDM4 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.